Henry Schein's FY2025 results show modest revenue growth to $13.2B and a slight EPS recovery to $3.27, but profitability remains well below 2021 peaks and debt has ballooned to $3.69B. The recent open-market purchase of 10,000 shares by the newly elected independent chairman at $69.19 signals insider confidence, while management highlights dental momentum and a $125M savings goal. However, the stock trades at a 26% PE premium to its sole provided peer DVA, and smart money interest is negligible, leaving the risk/reward balanced.
Elevated Leverage
Total debt increased from $1.22B in FY2021 to $3.69B in FY2025, while equity declined, raising financial risk and interest burden.
Medical Segment Softness
Management acknowledged softness in the medical business tied to a weaker respiratory illness season, which could persist and offset dental gains.
Margin Pressure
Operating income margin fell from 7.6% in FY2022 to 5.8% in FY2025, and net income remains below FY2021 levels despite higher revenue.
Valuation Premium
HSIC's PE of 21.6 and EV/EBITDA of 12.1 significantly exceed peer DVA's 17.1 and 9.3, respectively, limiting upside unless growth accelerates.